- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02196142
Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence (CAR-Bern 2013)
To investigate the effects of cortisol on alcohol craving and stress reactivity in alcohol addicted subjects.
Randomized, double-blind, placebo-controlled, cross-over, single administration of study medication.
Study hypothesis: Cortisol has an inhibiting effect on alcohol craving and stress reactivity in alcohol dependent subjects.
Study Overview
Status
Intervention / Treatment
Detailed Description
Background
Alcohol dependence is a chronically and relapsing disorder with major impact on the persons psychological, physiological and social functioning. There is extensive evidence from animal and human studies pointing out the important role of addiction memory in the development and maintenance of the disorder.
Cognitive behavioural therapy (CBT) has proven its high effectiveness in the treatment for addictive disorders. A core element of CBT are exposure techniques that are comparable to extinction and habituation learning. The repeated exposure to alcohol related cues in the absence of alcohol ingestion will lead to extinction of conditioned responses, thus reducing the probability of relapse to alcohol taking behaviour.
Studies have shown that glucocorticoids impair memory retrieval in healthy subjects. In fact, the investigators could show that cortisol has a fear reducing effect in patients with post-traumatic stress disorder and in phobic patients, resulting particularly in reduced symptoms of anxiety and in reduced stress reactivity. Interestingly enough, pharmacologically induced high levels of glucocorticoids lowered the subjective feeling of anxiety and stress in situations activating per se the HPA-axis. Further it has been shown that the combined therapy of glucocorticoid administration and exposition based psychotherapy leads to better therapy outcome in patients with specific phobias.
Objective
The goal of this study is to examine the acute effects of glucocorticoids administration on alcohol craving and stress reactivity of abstinent alcohol dependent patients. On the basis of clinical research in anxiety disorders, the investigators expect that a pharmacologically increased cortisol level may impair the retrieval of addiction memory, which is indicated by less craving during the alcohol exposition, while exposition therapy enhances consolidation of corrective experiences. Similar to the research in anxiety patients, the investigators aim to examine whether cortisol administration could help improve the effects of exposition therapy in patients with alcohol dependence. The purpose is to decrease therapy duration through cortisol administration in addition to already well proven therapies and make the therapy more efficient as well as a factor in reducing healthcare costs.
Methods
Patients undergo two identical experimental sessions between the 6th and 8th week (one week in between) of their 12-week inpatient treatment program for alcohol dependence. The experiment takes place in the experimental rooms of the clinic Südhang between 1 and 6 pm. One hour before the confrontation with alcohol associated stimuli patients receive either 20mg of hydrocortisone or placebo (oral administration). The experiment consists of a computer based picture task (alcoholic and neutral pictures) and an in-vivo exposure task. Psychological (craving, stress, arousal) and physiological (heart rate, saliva cortisol) parameters are repeatedly measured over the course of the experiment.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Bern
-
Kirchlindach, Bern, Switzerland, CH-3038
- Klinik Südhang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18
- Abstinent alcoholics in the 12-week in-patient program of the Clinic Südhang
- Abstained from alcohol for at least 6 weeks
- Voluntarily signed informed consent
Exclusion Criteria
- Co-morbid psychiatric disturbances (such as major depression, bipolar disorder, schizophrenia)
- Current medical conditions excluding participation (such as acute infectious disease)
- Recent history of systemic or topic glucocorticoid therapy
- Known hypersensitivity to the IMP under investigation (cortisol)
- Pregnancy, breast-feeding
- Inability to read and understand the participant's information
- Positive alcohol test according to breathalyser
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cortisol first, Placebo second
Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
|
Drug: Cortisol 20mg
Drug: Placebo Mannitol
|
Active Comparator: Placebo first, Cortisol second
Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
|
Drug: Cortisol 20mg
Drug: Placebo Mannitol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in alcohol craving score
Time Frame: During and after presentation of drug stimuli, expected to be after 10 minutes
|
Measured by Alcohol Urge Questionnaire & Visual Analogue Scale
|
During and after presentation of drug stimuli, expected to be after 10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in State-Trait-Anger Expression Inventory STAXI
Time Frame: After presentation of drug stimuli, expected to be after 20 minutes
|
After presentation of drug stimuli, expected to be after 20 minutes
|
Change from baseline in heart rate variability
Time Frame: During and after presentation of drug stimuli, expected to be after 10 minutes
|
During and after presentation of drug stimuli, expected to be after 10 minutes
|
Saliva Cortisol Level
Time Frame: After presentation of drug stimuli, expected to be after 90 minutes
|
After presentation of drug stimuli, expected to be after 90 minutes
|
Collaborators and Investigators
Investigators
- Study Director: Leila Soravia, Dr. phil., University Hospital of Psychiatry Bern
- Principal Investigator: Peter Allemann, Dr. med., Clinic Südhang
- Study Chair: Dominique de Quervain, Prof. Dr., University Hospital, Basel, Switzerland
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 068/14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychological Stress
-
New York State Psychiatric InstituteJohnson & JohnsonCompletedPsychological Stress in PregnancyUnited States
-
Baylor UniversityCompletedAcute Psychological StressUnited States
-
Örebro University, SwedenCompletedPsychological Stress Due to SkydivingSweden
-
Massachusetts General HospitalCompletedStress | Emotional Stress | Psychological Stress | Social Stress | Life StressUnited States
-
Amrita Vishwa VidyapeethamAmrita Viswa VidyapeethamCompletedCovid Related Psychological StressIndia
-
Institut de Recherche Biomedicale des ArmeesCompletedPsychological Stresses
-
University of California, San FranciscoNational Institute on Aging (NIA); Penn State University; Harvard UniversityCompletedStress | Depressive Symptoms | Psychological Distress | Psychological Stress | Signs and Symptoms | Psychological | Child MaltreatmentUnited States
-
Penn State UniversityStony Brook University; National Institute on Aging (NIA); Oregon State University and other collaboratorsCompleted
-
Military Academy at ETH ZurichSwiss Armed ForcesCompletedPsychological Stress | Psychological AdaptationSwitzerland
-
Nagoya City UniversityAichi Health Promotion FoundationCompleted
Clinical Trials on Cortisol 20mg
-
Onconic Therapeutics Inc.CompletedHealthyKorea, Republic of
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityCompleted
-
Anji PharmaCovanceCompletedFunctional ConstipationChina, United States
-
Medicines for Malaria VentureQ-Pharm Pty LimitedTerminatedMalaria, FalciparumAustralia
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Mitsubishi Tanabe Pharma CorporationCompletedType 2 Diabetes MellitusChina
-
University of California, San DiegoWithdrawnPost-traumatic Stress DisorderUnited States
-
PfizerCompletedHealthy Volunteers | Hepatic ImpairmentUnited States
-
Impact Therapeutics, Inc.Not yet recruiting
-
Seoul National University HospitalUnknown